On September 6, 2022 Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, reported that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace Hotel, New York, N.Y (Press release, Aravive, SEP 6, 2022, View Source [SID1234619052]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s presentation will be available for viewing on September 12, 2022, at 7:00 am ET. An archived replay of the webcast will be available for 90 days following the webcast on the Events & Presentations page of www.aravive.com. Aravive will also participate in one-on-one meetings at the conference.